Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by davewhoon Apr 03, 2021 4:47pm
151 Views
Post# 32934240

RE:RE:RE:RE:RE:RE:RE:Price on monday

RE:RE:RE:RE:RE:RE:RE:Price on mondayQ1 is on the books now and will be out next month along with the AGM. We should see another good bump up in rev and a get a clearer picture of how the Aristotle plan is unfolding. A few people have wondered if the Q4 delay was intentional. But Szls has a history of messing QR's up so probably not a viable theory. I agree if things had happened in a different order Thursday may never have been a problem. Q4 a couple days early showing the $2.8m, a CC highlighting increasing rev and Aristotle shortly. Then Care Oncology NR this coming week. Whole different out come? Probably. But in reality we are still the same company with the same huge potential we always had. 
<< Previous
Bullboard Posts
Next >>